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Abstract
Background: Bilharzia-associated bladder cancer (BAC) is a major health problem in countries
where urinary schistosomiasis is endemic. Characterization of the genetic alterations in this cancer
might enhance our understanding of the pathogenic mechanisms of the disease but, in contrast to
nonbilharzia bladder cancer, BAC has rarely been the object of such scrutiny. In the present study,
we aimed to characterize chromosomal imbalances in benign and malignant post-bilharzial lesions,
and to determine whether their unique etiology yields a distinct cytogenetic profile as compared
to chemically induced bladder tumors.
Methods: DNAs from 20 archival paraffin-embedded post-bilharzial bladder lesions (6 benign and
14 malignant) obtained from Sudanese patients (12 males and 8 females) with a history of urinary
bilharziasis were investigated for chromosomal imbalances using comparative genomic
hybridization (CGH). Subsequent FISH analysis with pericentromeric probes was performed on
paraffin sections of the same cases to confirm the CGH results.
Results: Seven of the 20 lesions (6 carcinomas and one granuloma) showed chromosomal
imbalances varying from 1 to 6 changes. The most common chromosomal imbalances detected
were losses of 1p21-31, 8p21-pter, and 9p and gain of 19p material, seen in three cases each,
including the benign lesion.
Conclusion: Most of the detected imbalances have been repeatedly reported in non-bilharzial
bladder carcinomas, suggesting that the cytogenetic profiles of chemical- and bilharzia-induced
carcinomas are largely similar. However, loss of 9p seems to be more ubiquitous in BAC than in
bladder cancer in industrialized countries.
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Background
Bladder cancer (BC) is the 5th and 7th most common ma-
lignancy among men and women, respectively, in Europe
and the United States, with transitional cell carcinoma
(TCC) dominating and accounting for more than 90% of
all cases [1]. In the Middle East and African sub-Sahara,
BC is the most common malignancy (25% of all cancers
in men), with a clear dominance (87%) of the squamous
cell carcinoma (SCC) sub-type [2]. In addition to the SCC
differentiation and more pronounced male preponder-
ance, a low mean age at diagnosis and rare involvement of
the trigonal region characterize BC in Africa and the Mid-
dle East [3]. The geographic and clinical differences in BC
behavior appear to be due mainly to etiologic differences:
Whereas chemicals, including cigarette smoke and occu-
pational exposures, cause TCC of the bladder in industri-
alized countries, a similarly strong association with
urinary bilharziasis exists in Africa and the Middle East
[4]. The mechanisms whereby urinary bilharziasis induces
BC are not fully understood, but elevated urinary N-ni-
troso compounds [5,6], elevated levels of B-glucuroni-
dase[7], and chronic mechanical irritation of the
urothelium by calcified eggs deposited in the bladder wall
have all been implicated [6–8].
In contrast to the extensive cytogenetic and molecular ge-
netic analyses that exist of bladder TCC in Western coun-
tries [9], little is known about the genetic alterations of
post-bilharzial BC [10]. Cytogenetic investigations require
in vitro culturing of tumor cells and therefore may be dif-
ficult to perform in areas with a high frequency of bilhar-
ziasis-associated BC (BAC). Comparative genomic
hybridization (CGH), on the other hand, is a powerful
molecular cytogenetic technique not dependent on the
presence of vital cells. The technique utilizes differentially
labeled tumor DNA and normal tissue DNA as competing
probes and normal metaphases as templates to detect and
localize gains and/or losses of genetic material across the
entire tumor genome [11]. Although CGH cannot detect
balanced chromosomal changes, its ability to identify ge-
nomic imbalances even in archival, paraffin-embedded
tumor materials [12] makes it uniquely well suited when
fresh samples are not available. Accordingly, we planned
the present experiment to characterize the genetic defects
underlying the development of BAC and to determine if
its distinct morphologic and clinical characteristics evolve
following genetic alterations different from those detected
in BC in industrialized countries.
Material and Methods
Tumor material
Fourteen formalin-fixed, paraffin-embedded blocks of
post-bilharzial bladder carcinomas (8 SCC and 6 TCC)
and 6 non-neoplastic bilharzia-associated bladder lesions
from 20 Sudanese patients (12 males and 8 females) were
obtained from the pathology archives of Ibn Sina Hospi-
tal and the National Health Laboratory at Khartoum, Su-
dan (Table 1). All patients had a history of chronic urinary
bilharziasis. No radiation therapy had been given before
tumor sampling. The tumors were classified histologically
according to the WHO (1973) grading system [13] and
staged in accordance with the UICC tumor-node-metasta-
sis (TNM) system [14].
CGH analysis
From each case, 20–30 paraffin sections (thickness 3–4
µm) were prepared for DNA extraction using the QIAamp
Tissue Kit (QIAGEN GmbH, Germany). The yield of DNA
was maximized with prolonged proteinase-K digestion ac-
cording to previously published protocols [12]. CGH
analysis was performed as previously described [11]. In
brief, tumor DNA samples were labeled with FITC-dUTP
(DuPont, Boston, MA, USA) by nick translation, whereas
normal reference DNA was labeled with Texas Red (Vysis
Inc., Downers Grove, IL, USA). In all cases, the tumor and
reference DNA samples were sex-matched. Tumor and ref-
erence DNA were mixed with unlabeled Cot-1 DNA (Gib-
co, BRLTM), denatured, and applied onto slides with
denatured metaphases of normal lymphocytes (Vysis
Inc.). After hybridization at 37°C for 48 h, the slides were
washed in 0.4 ×  SSC/0.3% NP-40 at 74°C for 2 min and
in 2 ×  SSC/0.1% NP-40 at room temperature for 1 min. Af-
ter air-drying, the slides were then counterstained with
DAPI (Vysis Inc.). Two control hybridizations were also
performed. In the first one, DNAs from a normal female
and a normal male were labeled and hybridized to normal
male metaphases. For the second experiment, DNA from
a previously characterized breast cancer cell line (MPE
600, Vysis Inc.) and DNA from a normal female were la-
beled and hybridized to normal male metaphases. Six to
10 three-color digital images (DAPI, FITC, and Texas Red
fluorescence) were collected from each hybridization us-
ing a Zeiss Axioplan 2 epifluorescence microscope (Carl
Zeiss Jena GmbH, Jena, Germany) and a Sensys charge-
coupled-device camera (Photometrics, Tucson, AZ, USA)
interfaced to an IPLab Spectrum 10 workstation (Signal
Analytics Corporation, Vienna, VA, USA). Interpretation
of CGH results was carried out as previously described.
Green-to-red ratios < 0.80 were considered to signify loss-
es of genetic material, ratios > 1.2 gains, and ratios >1.5
high-level amplifications. Heterochromatic regions, the
short arms of the acrocentric chromosomes, and the sex
chromosomes were not included in the evaluation.
Fluorescence in situ hybridization (FISH)
Pericentromeric probes for chromosomes X (pBAMX7), 9
(pHuR98), and 17 (p17H8) were labeled with FITC (Du-
Pont) and digoxigenin using nick translation. Prior to hy-
bridization, xylene and absolute ethanol were used to
remove the paraffin from the slides. After air-drying, theBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/5
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samples were pretreated with 0.01 M sodium citrate
(pH7.3) in 92°C for 10 min, followed by proteinase Indi-
gestion (10 mg in 2 ×  SSC) in 45°C for 30 min. The slides
were then rinsed in 2 ×  SSC, dehydrated in an ethanol se-
ries, and air-dried. The probes with human placental DNA
were denatured together with the slides on a hot plate at
75°C for 5 min, and hybridized at 37°C overnight. After
washing and detection of digoxigenin with anti-digoxi-
genin rhodamine, the slides were counterstained with 0.1
µM 4,6-diamino-2-phenylindole (DAPI) in an antifade
solution (Vectashield, Vector Laboratories, Burlingame,
CA, USA). The analysis was performed using an Olympus
epifluorescence microscope equipped with a CCD camera
(Photometrics).
Results
The clinical, histopathologic, CGH, and FISH findings are
summarized in Table 1 and Figures 1,2,3. The pathologic
examination showed calcified bilharzial ova in at least 8
of the cases as a direct indication of urinary bilharziasis
(Figures 1 and 2). The CGH results were generally charac-
terized by a low number of genomic alterations. Of the 20
cases, 6 carcinomas (4 SCC and 2 TCC) and one benign le-
sion (bilharzial granuloma) showed chromosomal imbal-
ances varying from 1 to 6 changes. In the remaining 13
samples, no DNA copy number changes could be detect-
ed. The most frequent changes (3 cases) were of chromo-
somes 1, 8, 9, and 19, with losses being observed from the
short arms of chromosomes 1, 8, and 9 and gains of ma-
terial from 19p. The FISH analyses performed on nuclei
extracted from sectioned slides of 12 cases were consistent
with the CGH findings (Table 1).
Discussion
Schistosomiasis is endemic in 74 tropical developing
countries. Some 600 million of the world's population
run the risk of becoming infected, of which 200 million
are already infected. In most of the cases, infestation with
Table 1: 
Histopathology FISH CGH imbalances
Lab No Sex/Age Type Grade Stage Other Losses Gains
Benign
747–98 M/65 Ch. inflammation
738–98 F/53 Ch. inflammation
162–99 M/70 Ch. Inflammation Moderate dysplasia
548–98 M/51 Granuloma CBO
352–99 F/55 Granuloma CBO Xc 3, AR 1
286–98 M/45 Granuloma with inflammatory polyp 9c 1, 17c 2 9p, 16p, 22q
Malignant
453–99 F/49 SCC G1 ? CBO topo 1
2228–99 F/60 SCC G1 CBO 9c 1, 17c 3, Xc 3 1 cen-p31, 
3p,9pter-q13
19p
229–99 M/70 SCC G2 T3 KCs Xc 2, 17c 2
210–99 M/70 SCC G3 T3 KCs
471–99 M/60 SCC G3 ? CBO+SM Xc 2, 17c 3
217–98 F/51 SCC G3 T3 CBO 9p
476–98 M/53 SCC G3 T3 CBO 9c 2, 17c 3 1p21-p22, 2q13-
q21, 8p, 13q, 18q
19p
479–98 M/47 SCC G2–3 CBO 2q13-q21, 8p 19p
345–98 M/61 TCC G1 ? CBO+SM
240–98 F/55 TCC G2 ? Xc 1, 9c 2,17c 2
746–98 F/60 TCC G2 Xc 2–3, 9c2–3, 
17c 2–6(4)
4540–98 M/62 TCC G2 ?
5605–97 M/50 TCC G3 T3 SM Xc 2, AR 3–5 8p21-pter
5653–98 F/50 TCC G3 T3 Xc 1–3, 9c 2, 
17c 2
1 cen-p31 5p, 
17q, 
20q
SCC, squamous cell carcinoma; TCC, transitional cell carcin oma; G1, well differentiated; G2, moderately differentiated; G3, poorly differ entiated; 
CBO, calcified bilharzial ova; I K:Cs, keratinzed cells; SM, squamous metaplaBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/5
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schistosomiasis leads to damage of the urothelium, which
results in permanent loss of mature, superficial cells and
an increased rate of cell division, eventually leading to the
formation of a hyperplastic urothelium consisting of im-
mature cells. The disturbed cellular differentiation pattern
thus gives rise to a variety of non-cancerous phenotypes
with a pronounced tendency to undergo malignant trans-
formation.
Compared with banding cytogenetics that has the capacity
to provide detailed information on balanced as well as
unbalanced chromosomal rearrangements, even in cases
displaying intratumor clonal heterogeneity, CGH can
only detect genomic imbalances present in major tumor
clones [15]. On the other hand, CGH is superior in the
sense that it can be applied to both fresh and frozen tumor
samples as well as to formalin-fixed and paraffin-embed-
ded materials [16], thereby circumventing the culturing
process with the technical and selection problems this in-
volves and which may cause considerable interpretation
difficulties in conventional cytogenetic analysis. In 13 of
the studied bladder lesions (4 SCC, 4 TCC, and 5 non-ma-
lignant lesions), no chromosomal imbalances were de-
tected, indicating that the genetic alterations, if any
existed, were qualitatively or quantitively beyond the de-
tection limits of the CGH method. However, the positive
results in the remaining 7 cases (4 SCC, 2 TCC, and 1
granuloma) demonstrate the capacity of CGH to detect
chromosomal imbalances in tumor DNA obtained from
archival materials. In the 11 cases in which FISH analysis
with pericentromeric probes was performed, the results
were consistent with those obtained by CGH analysis. In
two cases (471–99 and 746–98), however, the FISH ex-
amination revealed chromosomal imbalances that had
not been detected in the previous CGH analysis (Figure
3). The explanation for this discrepancy could be that too
few neoplastic cells were present in the sample or that sec-
ondary intratumor genetic heterogeneity had arisen, again
preventing the CGH results from reaching beyond the de-
tection thresholds.
Figure 1
Histologic section from invasive squamous cell carcinoma
(case 217–98). Schistosoma haematobium eggs (arrows)
embedded in bladder urothelium confirm the previous infes-
tation with urinary schistosomiasis.
Figure 2
Histologic section from patient bladder with active urinary
bilharziasis (case 286–98). Arrowheads indicate calcified bil-
harzial ova embedded in bladder urothelium.
Figure 3
The CGH profiles and FISH results in case 746–98. The CGH
profiles of chromosomes 1 and 17 with thresholds 1.2 and
0.8 are shown in panel A. The CGH profiles of chromo-
somes 1 and 17 with thresholds 1.15 and 0.85 are shown in
panel B. Two different cell populations are seen by FISH,
shown in panel C. The centromere probes for chromosomes
1 and 17 were labeled by FITC and Rhodamine, respectively.
Two signals of both probes are seen above and four signals of
Icen and six signals of 17 cen are seen below.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/5
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Several preneoplastic urothelial lesions may precede the
development of BAC such as inflammatory polyp, bilhar-
zial granuloma, and bilharzial ulcer. To our knowledge,
no data are available on the karyotypic characteristics of
these lesions. Preneoplastic lesions in other organs have
been shown to harbor nonrandom acquired genetic aber-
rations; in fibrocystic disease of the breast, for instance,
cytogenetic studies have revealed clonal chromosomal ab-
normalities resembling the ones detected in carcinomas
of the same organ [17]. Hence, another objective of the
present study was to find out if benign bilharzial bladder
lesions also carry chromosomal aberrations, and if they
do, whether they resemble those seen in bladder carcino-
mas. Such changes, if present, would presumably consti-
tute the earliest steps of a putative multistage cascade of
post-bilharzial carcinogenesis [18]. Of the 6 non-neoplas-
tic lesions examined, 5 were noninformative, in-as-much
as no gains or losses were detected, and only in case 286–
98 were chromosomal imbalances seen, one of them loss
of 9p. The data are of course meager, but viewed in concert
with what has already been reported [19–21], they come
across as meaningful. Thus, loss of material from 9p in
both malignant and non-malignant bilharzial lesions ap-
pears to be an initiating event in BAC. However, several
have shown that loss of 9p (without loss of 9q) is a com-
mon genetic event in advanced, muscle invasive TCC, and
since most (80%) BACs are advanced as far as grade and
stage are concerned, loss of material from 9p may be seen
more frequently in these carcinomas [22–25].
With the exception of the gain of chromosome material
from 19p observed in three cases (2228–99, 476–98, and
479–98), almost all changes detected in our series (com-
plete or partial loss of 1p, 8p, 9p, and 13q, and gain of 5p,
17q, and 20q) have been previously reported as recurrent
genetic changes in chemically induced TCC of the bladder
[9]. However, the gain of 19p should be interpreted with
caution since this chromosome is prone to hybridization
variability that may result in CGH artifacts. For the latter
aberrations, the available data therefore indicate that they
form part of a pathogenetic pathway followed by both
BAC and chemical carcinogen-induced BC. A previous
study reported homozygous deletions at 9p without any
involvement of 9q in 92% of bilharzial carcinomas ob-
tained from Egyptian patients compared with only 10% in
bladder TCC obtained from Swedish patients [19]. In the
same study, the type and position of TP53 mutations also
differed between the two tumor types, again suggesting
molecular differences in the genetic mechanisms of blad-
der carcinogenesis depending on underlying etiology.
Tsutsumi et al. [21] also suggested that loss of 9p21 heter-
ozygosity was associated with early carcinogenesis of SCC
of the bladder; they observed homozygous deletion of
p16/p19 in 45% of squamous metaplasia from bladder
cancer patients, demonstrating that this change occurred
already in preneoplastic cells. Muscheck et al. [26]
reached the same conclusion, and showed that different
histologic subgroups of bladder tumors are characterized
by distinct patterns of chromosomal alterations. The loss
of 9p we observed in bilharzia-associated lesions is there-
fore in complete agreement with earlier findings [19–25]
and could be an indication that bladder carcinogenesis
with this etiology follows a more narrow pathogenetic
pathway (loss of 9p) than is the case for BC in the indus-
trialized world (the earliest genomic change in these tu-
mors is loss of 9p, loss of 9q or loss of the entire
chromosome).
At the time of the first diagnosis, more than 80% of BAC
present as bulky fungating nodular tumor masses with
deep infiltration into the bladder wall. This necessitates
radical cystectomy and urinary diversion. Unfortunately,
at this late stage even these extensive therapeutic measures
are rarely curative and long-term survival is obtained only
in about 27–39% of the cases. It is clear that BAC is a po-
tentially preventable disease, but until the means are
found to achieve primary prevention through the control
of schistosomiasis, one is dependent on earlier diagnosis,
which means that a test for early detection of malignancy
in high-risk groups, especially for the detection of early tu-
mor stages, is badly needed. One can envisage the use of a
molecular genetic test based on the consistent loss of 9p
in cells detected in the urine for such screening purposes.
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